Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05664217 · ClinicalTrials.gov registry record · Phase 2
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
A Phase 2 study, sponsored by Nektar Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT05664217 is a Phase 2 study that was terminated before completion, run by Nektar Therapeutics. The registered enrollment target is 15 participants.
The verdict
NCT05664217, a Phase 2 study, was terminated before completion, sponsored by Nektar Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer. T cells are infection fighting blood cells that can kill tumor cells. Chimeric antigen (CAR)-T cell product consists of genetically engineered T-cells, modified to recognize CD19, a protein on the surface of cancer cells. These CD19-specific T cells may help the body's immune system identify and kill CD19-positive cancer cells. Giving NKTR-255 following the treatment with CD19 CAR-T cell therapy may work better in treating large B-cell lymphoma than either drug alone.
Interventions
- OTHER Placebo Comparator
- DRUG NKTR-255 at 1.5 µg/kg
- DRUG NKTR-255 at 3.0 μg/kg
- DRUG NKTR-255 at 3.0/6.0 μg/kg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2022-12-23 |
| Est. Completion | 2024-08-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05664217
The ClinicalTrials.gov registry entry for NCT05664217 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo Comparator is the first listed.
NCT05664217 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05664217 about?
NCT05664217 is a clinical study titled "NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma". This study will evaluate the safety and efficacy of NKTR-255 following CD19-directed chimeric antigen (CAR)-T cell therapy in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL). NKTR-255 is an investigational IL-15 receptor agonist designed to boost the immune system's natural ...
What is the current status of trial NCT05664217?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2022-12-23. Estimated completion is 2024-08-16.
What interventions are being tested in trial NCT05664217?
The interventions under investigation include: Placebo Comparator (OTHER), NKTR-255 at 1.5 µg/kg (DRUG), NKTR-255 at 3.0 μg/kg (DRUG), NKTR-255 at 3.0/6.0 μg/kg (DRUG).
Who is sponsoring clinical trial NCT05664217?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.